A hostile tumor microenvironment, usually mediated by diverse immunosuppressive factors including the local secretion of immunosuppressive cytokines, such as transforming growth factor β (TGF-β) and interleukin 10 (IL-10), as well as the downregulation of surface major histocompatibility complex (MHC) class I molecules on malignant cells [34,35,36,37], may be responsible for limiting the efficacy of the antitumor immune response. This evidence concerns the gene IL10 and neoplasm.